Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.
Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.
Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.
Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.
For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.
Allurion Technologies and Compute Health Acquisition Corp (NYSE: CPUH) have entered into a business combination agreement, positioning Allurion to become publicly listed as Allurion Technologies, Inc. This innovative company is focused on obesity treatment, featuring the Allurion Gastric Balloon, a swallowable gastric balloon that allows for procedure-less weight loss. Since its inception, Allurion has treated over 100,000 patients worldwide, achieving an average weight loss of 30 pounds. Revenue has surged from $20 million in 2020 to $64 million in 2022. The transaction includes significant investments from RTW Investments and other notable figures.
Establishment Labs (NASDAQ: ESTA) announced preliminary unaudited revenue results for Q4 and FY 2022, projecting Q4 revenue between
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a strategic partnership with Seishin Plastic and Aesthetic Surgery Clinic in Japan, launching Mia Femtech, a minimally invasive breast aesthetics procedure. This collaboration aims to address dissatisfaction among Japanese women regarding breast aesthetic options, potentially expanding the market significantly. The Mia procedure can enhance breast shape by 1 to 2 cup sizes in just 15 minutes, without general anesthesia. While currently not approved for commercial distribution in the U.S., this launch represents the first of many anticipated in 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12 at 7:30 a.m. Pacific Time. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible post-event. Establishment Labs specializes in women’s health technology, focusing on breast aesthetics and reconstruction, and has delivered over 2.5 million Motiva Implants® globally since 2010.
Establishment Labs Holdings (NASDAQ: ESTA) recently announced the approval of Motiva Implants® and the Motiva Flora® tissue expander for use in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA). These products have also secured reimbursement under the Japanese National Health System for post-mastectomy reconstruction. The first patient was treated successfully in November at Nagoya University Hospital. This launch signifies a commitment to enhancing women's health through innovative products backed by clinical data.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported third quarter 2022 sales of $38.2 million, a year-over-year increase of 31.7%. Revenue guidance for 2022 has been narrowed to $158 million to $162 million, reflecting 25% to 28% growth from 2021, with foreign exchange effects expected to reduce revenue by $6.5 million. Gross profit margin improved to 68.1%, while operating expenses rose 27.5% to $36.6 million. The company holds a cash balance of $65.3 million as of September 30, 2022, and plans to commercialize Mia Femtech™ and seek FDA approval for Motiva Implants in early 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Jefferies London Healthcare Conference and the Stephens Annual Investment Conference, both taking place from November 15-17, 2022. CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Jefferies conference on November 15 at 5:00 PM GMT, while Denhoy will speak at the Stephens conference on November 17 at 11:00 AM CT. Live webcasts and archived versions of the presentations will be available on the company's investor relations website.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2022 on November 7, 2022, after market close. A conference call will be held at 4:30 pm ET to discuss these results. The company specializes in breast aesthetics and reconstruction, offering advanced silicone gel-filled implants, Motiva Implants®, with over 2 million implants distributed in over 80 countries since 2010. The company aims to continue improving women's health through innovative products.
Holzer & Holzer, LLC is investigating Establishment Labs Holdings Inc. (NASDAQ:ESTA) for potential compliance failures with federal securities laws. Following a report by Hindenburg Research, which alleged undisclosed conflicts of interest in key safety studies of Establishment Labs' breast implants, the company's stock price experienced a decline. The report claims significant pushback was received by a surgeon for publishing higher complication rates than those reported by the company. Shareholders who incurred losses are encouraged to contact Holzer & Holzer for potential legal recourse.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will host an investor event on October 5, 2022, at 4:30 p.m. ET, to discuss its innovative product, Mia Femtech®. This minimally invasive procedure aims to enhance breast aesthetics, allowing for a breast size increase of 1 to 2 cups in just 15 minutes, without general anesthesia. The company is pursuing regulatory approvals for Mia in Europe and anticipates commercialization in select markets in the first half of 2023.
FAQ
What is the current stock price of Establishment Labs Holdings (ESTA)?
What is the market cap of Establishment Labs Holdings (ESTA)?
What does Establishment Labs Holdings Inc. specialize in?
What is the flagship product of Establishment Labs?
In which regions does Establishment Labs operate?
How does Establishment Labs distribute its products?
What are the recent achievements of Establishment Labs?
What is the focus of Establishment Labs' ongoing projects?
How long has Establishment Labs been in the breast implant manufacturing industry?
What sets Motiva Implants® apart from other products in the market?
Is Establishment Labs a publicly traded company?
Where can I find the latest news about Establishment Labs Holdings Inc.?
